This study looked at how weekly semaglutide (Ozempic) affected patients with type 2 diabetes (T2D) in a real-world setting. It found that semaglutide improved blood sugar control compared to the treatments patients were already taking.

The main objectives of this study was to determine the long term effect and safety of lixisenatide (Lyxumia) as an add-on therapy in type 2 diabetes. The authors concluded that lixisenatide provided long-term blood sugar control, reduced weight and was a safe method of treatment in patients with type 2 diabetes.

This study examined whether an intense lifestyle intervention in type 2 diabetic patients was associated with increased bone loss.

This study investigated whether race and ethnicity affect inflammation levels in diabetes patients The authors also investigated whether inflammation levels were associated with early chronic kidney disease. 

This study examined the whether body mass index prior to weight loss affected the incidence of diabetes remission.

The authors aimed to analyze data available on type 2 diabetes and osteoporosis (condition that causes bone fragility) and determine the best treatment course to avoid osteoporosis development. The authors concluded that type 2 diabetes moderately increases the risk of fracture, and that new treatments that have a neutral or positive effect on bone health are needed.

This study examined whether alogliptin is safe and effective as an add-on therapy to metformin in patients with type 2 diabetes who require more intense control of blood glucose levels. The authors concluded that patients with type 2 diabetes who fail metformin single treatment are more likely to achieve better control of blood glucose levels with alogliptin compared to glipizide.

This study examined the effectiveness of adding henagliflozin (SHR3824) to metformin (Glucophage) in patients with uncontrolled type 2 diabetes (T2D). The authors concluded that the addition of 5 mg or 10 mg of henagliflozin to metformin was well-tolerated and effective in these patients. 

This study investigated the effectiveness of three different approaches to control blood pressure in overweight and obese type 2 diabetes patients. 

This study evaluated the effects of lansoprazole on metformin pharmacokinetics (absorption, distribution, metabolism and excretion) in healthy humans.